Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial
European Journal of Nuclear Medicine and Molecular Imaging · 2024
DOI: 10.1007/s00259-024-06683-0 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Antonio Llombart-Cussac und 20 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Arnau de Vilanova, FISABIO, Valencia, Spain. antoniollombart@medsir.org. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Positron-Emission Tomography. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F. Hoffmann-La Roche.
Abstract (Originalsprache)
Background
The PHERGain study (NCT03161353) is assessing early metabolic responses to neoadjuvant treatment with trastuzumab-pertuzumab and chemotherapy de-escalation using a [ 18 Fluorine]fluorodeoxyglucose-positron emission tomography ([ 18 F]FDG-PET) and a pathological complete response-adapted strategy in HER2-positive (HER2+) early breast cancer (EBC). Herein, we present RESPONSE, a PHERGain substudy, where clinicopathological and molecular predictors of [ 18 F]FDG-PET disease detection were evaluated.
Methods
A total of 500 patients with HER2 + EBC screened in the PHERGain trial with a tumor size > 1.5 cm by magnetic resonance imaging (MRI) were included in the RESPONSE substudy. PET[−] criteria entailed the absence of ≥ 1 breast lesion with maximum standardized uptake value (SUVmax) ≥ 1.5 × SUVmean liver + 2 standard deviation. Among 75 PET[−] patients screened, 21 with SUVmax levels < 2.5 were randomly selected and matched with 21 PET[+] patients with SUVmax levels ≥ 2.5 based on patient characteristics associated with [ 18 F]FDG-PET status. The association between baseline SUVmax and [ 18 F]FDG-PET status ([−] or [+]) with clinicopathological characteristics was assessed. In addition, evaluation of stromal tumor-infiltrating lymphocytes (sTILs) and gene expression analysis using PAM50 and Vantage 3D™ Cancer Metabolism Panel were specifically compared in a matched cohort of excluded and enrolled patients based on the [ 18 F]FDG-PET eligibility criteria.
Results
Median SUVmax at baseline was 7.2 (range, 1–39.3). Among all analyzed patients, a higher SUVmax was associated with a higher tumor stage, larger tumor size, lymph node involvement, hormone receptor-negative status, higher HER2 protein expression, increased Ki67 proliferation index, and higher histological grade ( p < 0.05). [ 18 F]FDG-PET [−] criteria patients had smaller tumor size ( p = 0.014) along with the absence of lymph node involvement and lower histological grade than [ 18 F]FDG-PET [+] patients ( p < 0.01). Although no difference in the levels of sTILs was found among 42 matched [ 18 F]FDG-PET [−]/[+] criteria patients ( p = 0.73), [ 18 F]FDG-PET [−] criteria patients showed a decreased risk of recurrence (ROR) and a lower proportion of PAM50 HER2-enriched subtype than [ 18 F]FDG-PET[+] patients ( p < 0.05). Differences in the expression of genes involved in cancer metabolism were observed between [ 18 F]FDG-PET [−] and [ 18 F]FDG-PET[+] criteria patients.
Conclusions
These results highlight the clinical, biological, and metabolic heterogeneity of HER2+ breast cancer, which may facilitate the selection of HER2+ EBC patients likely to benefit from [ 18 F]FDG-PET imaging as a tool to guide therapy.
Trial registration
Clinicaltrials.gov; NCT03161353; registration date: May 15, 2017.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Arnau de Vilanova, FISABIO, Valencia, Spain. antoniollombart@medsir.org.
- Universidad Católica de Valencia, Valencia, Spain. antoniollombart@medsir.org.
- Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain. antoniollombart@medsir.org.
- Hospital Clínic i Provincial de Barcelona, Barcelona, Spain.
- University of Barcelona, Barcelona, Spain.
- Translational Genomics and Targeted Therapies in Solid Tumors Lab., Barcelona, Spain.
ORCID-Profile: Antonio Llombart-Cussac
Förderung
- F. Hoffmann-La Roche
Zitieren
APA
Llombart-Cussac, A., Prat, A., Pérez-García, J. M., Mateos, J., Pascual, T., Escrivà-de-Romani, S., Stradella, A., Ruiz-Borrego, M., de Las Heras, B. B., Keyaerts, M., Galvan, P., Brasó-Maristany, F., García-Mosquera, J. J., Guiot, T., Gion, M., Sampayo-Cordero, M., Di Cosimo, S., Pérez-Escuredo, J., de Frutos, M. A., …, & Gebhart, G. (2024). Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06683-0
Vancouver
Llombart-Cussac A, Prat A, Pérez-García JM, Mateos J, Pascual T, Escrivà-de-Romani S, et al. Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06683-0
BibTeX
@article{LlombartCussac2024,
author = {Llombart-Cussac, Antonio and Prat, Aleix and Pérez-García, José Manuel and Mateos, José and Pascual, Tomás and Escrivà-de-Romani, Santiago and Stradella, Agostina and Ruiz-Borrego, Manuel and de Las Heras, Begoña Bermejo and Keyaerts, Marleen and Galvan, Patricia and Brasó-Maristany, Fara and García-Mosquera, Juan José and Guiot, Thomas and Gion, María and Sampayo-Cordero, Miguel and Di Cosimo, Serena and Pérez-Escuredo, Jhudit and de Frutos, Manuel Atienza and Cortés, Javier and Gebhart, Geraldine},
title = {Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
doi = {10.1007/s00259-024-06683-0}
}
EUVIMED